Article Contents ::
- 1 The Brand Name REGUBEAT Has Generic Salt :: Disopyramide
- 2 REGUBEAT Is From Company GSK Priced :: Rs. 107.5
- 3 REGUBEAT have Disopyramide is comes under Sub class Anti Arrhythmics of Main Class Cardiovascular System
- 4 Main Medicine Class:: Cardiovascular System Sub Medicine Class :: Anti Arrhythmics
- 5 Disclaimer ::
- 6 The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.
The Brand Name REGUBEAT Has Generic Salt :: Disopyramide
REGUBEAT Is From Company GSK Priced :: Rs. 107.5
REGUBEAT have Disopyramide is comes under Sub class Anti Arrhythmics of Main Class Cardiovascular System
Main Medicine Class:: Cardiovascular System Sub Medicine Class :: Anti Arrhythmics
Salt Name : OR Generic Name | Form | Price : MRP /Probable | Packing | ||
Disopyramide | TAB | Rs. 107.5 | 30 |
Brand Name | Company / Manufacturers | Strength | Unit | Price / 30 |
REGUBEAT | GSK | 100MG | 30 | Rs. 107.5 |
Company Brand Name | Salt Combination | Main Medical Class | Sub Medical Class |
From GSK :: REGUBEAT | Disopyramide | Cardiovascular System | Anti Arrhythmics |
Indications for Drugs ::
Ventricular tachycardia, Supraventricular and Ventricular arrhythmias
Drug Dose ::
Oral Supraventricular and ventricular arrhythmias Adult: 300-800 mg daily in divided doses (as conventional capsules every 6 hr; as extended-release capsules every 12 hr), adjusted according to patient’s response. Child: 12-18 yr: 6-15 mg/kg daily; 4-12 yr: 10-15 mg/kg daily; 1-4 yr: 10-20 mg/kg daily; <1 yr: 10-30 mg/kg daily. Renal impairment: CrCl (ml/min) >40 400 mg daily in divided doses. 30-40 100 mg every 8 hr; avoid modified release preparations. 15-30 100 mg every 12 hr; avoid modified release preparations. <15 100 mg every 24 hr; avoid modified release preparations. Hepatic impairment: 400 mg daily in divided doses. Liver cirrhosis: consider a therapeutic range 50% lower than in patients with normal hepatic function. Contraindication ::
Patients with complete heart block; glaucoma; predisposition to urinary retention; myasthenia gravis. Sinus node disease in absence of pacemaker. Cardiomyopathy. Cardiogenic shock. Hypotension. Hypersensitivity. Children.
Drug Precautions ::
Conduction disorders or uncompensated heart failure. Pregnancy and lactation. Renal and hepatic failure. Family history of glaucoma. Correct potassium deficiency.
Drug Side Effects ::
Impotence, constipation, difficulty in micturition, dry mouth, blurred vision, nausea, bloating, abdominal pain, vomiting, diarrhoea, colic. Psychosis, depression, skin rashes, dizziness, fatigue, muscle weakness, headache, cholestatic jaundice, elevated liver enzymes, thrombocytopenia, agranulocytosis, ventricular tachycardia and fibrillation, heart failure, hypotension, conduction disturbances. Potentially Fatal: Urinary retention, severe cardiovascular depression if given as rapid IV inj. High risk of recurrence of failure in patients with history of congestive cardiac failure. Negative inotropic effect especially prominent in patients with cardiomyopathy, hypertension and uncompensated cardiac failure.
Pregnancy category ::
3
Drug Mode of Action ::
Disopyramide is a Ia antiarrhythmic agent which acts by decreasing myocardial excitability and conduction velocity. It lengthens the effective refractory period of the atrium. It also possesses antimuscarinic and negative inotropic effects.
Drug Interactions ::
Avoid other Class I antiarrhythmics and other cardiac depressants including ?-blockers except in life-threatening arrhythmias. Risk of worsening of arrhythmias, precipitation of new arrhythmias and ventricular fibrillation when used with other anti-arrhythmics. Reduced efficacy when co-admin with phenytoin. Potentially Fatal: Enhanced antimuscarinic effects with other antimuscarinic drugs. Potentiates negative chronotropic and inotropic effects of ?-blockers and verapamil. Potentiates inhibitory effect on the conduction system produced by digitalis. Potentiates QT interval prolongation produced by TCAs and amiodarone.